| External factors: | Atorvastatin |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | SA-β-gal activity assay//BrdU assay |
| Description: | Treatment with atorvastatin, pravastatin, or pitavastatin inhibited the senescent phenotype at 10 days.In parallel with this, an increased rate of 5-bromodeoxyuridine (BrdU) (index of proliferation) incorporation and telomerase activity were restored by treatment with atorvastatin, pravastatin, and pitavastatin. |
| Target gene: | SIRT1//ENOS |
| R-EF-Target gene: | Upregulation//Activation |
| Official symbol(s): | SIRT1//ENOS |
| Target gene experiment: | Western blot |
| Target gene description: | In the presence of H2O2, treatment with atorvastatin, pravastatin, and pitavastatin increased eNOS expression dose dependently. In parallel with eNOS expression, activity of eNOS was increased by treatment with atorvastatin,We found that atorvastatin, pravastatin, and pitavastatin significantly increased SIRT1 expression in a concentration-dependent manner for 10 days after treatment with H2O2. |
| Regulatory pathway: | Akt |
| R-EF-Pathway: | -- |
| Official symbol(s): | AKT1 |
| Pathway experiment: | Western blot |
| Pathway description: | Treatment with atorvastatin, pravastatin, or pitavastatin increased the phosphorylation of Akt at Ser473. |
Annotation: